Cargando…

Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels

Ovarian cancer (OC) is the second most common gynecologic malignancy. A clinical observational study was performed to investigate whether indicators that assess the risk of metastasis can identify recurrence earlier in OC patients. By successfully recruiting 41 patients with OC who underwent chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fei, Zhao, Xuejun, Tan, Wenhua, Liu, Wei, Jin, Yuxia, Liu, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6228545/
https://www.ncbi.nlm.nih.gov/pubmed/30425896
http://dx.doi.org/10.7717/peerj.5912
_version_ 1783370030236303360
author Wang, Fei
Zhao, Xuejun
Tan, Wenhua
Liu, Wei
Jin, Yuxia
Liu, Qian
author_facet Wang, Fei
Zhao, Xuejun
Tan, Wenhua
Liu, Wei
Jin, Yuxia
Liu, Qian
author_sort Wang, Fei
collection PubMed
description Ovarian cancer (OC) is the second most common gynecologic malignancy. A clinical observational study was performed to investigate whether indicators that assess the risk of metastasis can identify recurrence earlier in OC patients. By successfully recruiting 41 patients with OC who underwent chemotherapy, we compared cancer antigen-125 (CA-125) and the ovarian cancer metastasis index (OCMI), which was previously developed by us in the clinic for this purpose. Our results showed that patients and their families generally took a sensible attitude toward disease progression and were willing to accept a new way to gain knowledge about the disease. Herein, the new way was the possibility of monitoring recurrence by introducing the OCMI into the clinic. Fifteen patients experienced recurrence during chemotherapy, implying treatment failure. For 53% of these patients, an abnormally high OCMI suggested a strong tendency toward metastasis at least one chemotherapy cycle prior to the pathological examination confirming recurrence. In comparison, the early recognition rate of recurrence using CA-125 levels was merely 13%. Furthermore, we found that the mean values of the OCMI no longer declined after the fourth chemotherapy cycle, implying that excessive chemotherapy brings no benefit to OC patients. In conclusion, our findings provide a novel and feasible approach to monitor the effectiveness of chemotherapy in the treatment of OC by assessing the potential risk of metastasis.
format Online
Article
Text
id pubmed-6228545
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-62285452018-11-13 Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels Wang, Fei Zhao, Xuejun Tan, Wenhua Liu, Wei Jin, Yuxia Liu, Qian PeerJ Gynecology and Obstetrics Ovarian cancer (OC) is the second most common gynecologic malignancy. A clinical observational study was performed to investigate whether indicators that assess the risk of metastasis can identify recurrence earlier in OC patients. By successfully recruiting 41 patients with OC who underwent chemotherapy, we compared cancer antigen-125 (CA-125) and the ovarian cancer metastasis index (OCMI), which was previously developed by us in the clinic for this purpose. Our results showed that patients and their families generally took a sensible attitude toward disease progression and were willing to accept a new way to gain knowledge about the disease. Herein, the new way was the possibility of monitoring recurrence by introducing the OCMI into the clinic. Fifteen patients experienced recurrence during chemotherapy, implying treatment failure. For 53% of these patients, an abnormally high OCMI suggested a strong tendency toward metastasis at least one chemotherapy cycle prior to the pathological examination confirming recurrence. In comparison, the early recognition rate of recurrence using CA-125 levels was merely 13%. Furthermore, we found that the mean values of the OCMI no longer declined after the fourth chemotherapy cycle, implying that excessive chemotherapy brings no benefit to OC patients. In conclusion, our findings provide a novel and feasible approach to monitor the effectiveness of chemotherapy in the treatment of OC by assessing the potential risk of metastasis. PeerJ Inc. 2018-11-07 /pmc/articles/PMC6228545/ /pubmed/30425896 http://dx.doi.org/10.7717/peerj.5912 Text en ©2018 Wang et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Gynecology and Obstetrics
Wang, Fei
Zhao, Xuejun
Tan, Wenhua
Liu, Wei
Jin, Yuxia
Liu, Qian
Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
title Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
title_full Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
title_fullStr Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
title_full_unstemmed Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
title_short Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
title_sort early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and ca-125 levels
topic Gynecology and Obstetrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6228545/
https://www.ncbi.nlm.nih.gov/pubmed/30425896
http://dx.doi.org/10.7717/peerj.5912
work_keys_str_mv AT wangfei earlyidentificationofrecurrenceinovariancanceracomparisonbetweentheovariancancermetastasisindexandca125levels
AT zhaoxuejun earlyidentificationofrecurrenceinovariancanceracomparisonbetweentheovariancancermetastasisindexandca125levels
AT tanwenhua earlyidentificationofrecurrenceinovariancanceracomparisonbetweentheovariancancermetastasisindexandca125levels
AT liuwei earlyidentificationofrecurrenceinovariancanceracomparisonbetweentheovariancancermetastasisindexandca125levels
AT jinyuxia earlyidentificationofrecurrenceinovariancanceracomparisonbetweentheovariancancermetastasisindexandca125levels
AT liuqian earlyidentificationofrecurrenceinovariancanceracomparisonbetweentheovariancancermetastasisindexandca125levels